Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
- 10 November 2011
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (32), e792-e794
- https://doi.org/10.1200/jco.2011.36.9199
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesThe Journal of Experimental Medicine, 2009
- PD-1 and CTLA-4 Inhibitory Cosignaling Pathways in HIV Infection and the Potential for Therapeutic InterventionPublished by The American Association of Immunologists ,2009
- Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992–2003Annals of Internal Medicine, 2008
- Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus InfectionPublished by The American Association of Immunologists ,2008
- Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunctionNature Immunology, 2007
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Klinische Entwicklung zielgerichteter molekularer KrebstherapeutikaOnkologie, 2005
- Altered Clinical Course of Malignant Melanoma in HIV-Positive PatientsArchives of Dermatology, 2002
- Modulation of Susceptibility to HIV-1 Infection by the Cytotoxic T Lymphocyte Antigen 4 Costimulatory MoleculeThe Journal of Experimental Medicine, 1999